Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice

• Published in: PloS one 2015-05, Vol.10 (5), p.e0126599-e0126599
• Main Authors: Kjær, Thomas Nordstrøm, Thorsen, Kasper, Jessen, Niels, Stenderup, Karin, Pedersen, Steen Bønløkke
• Format: Article
• Language: English
• Subjects: Acids; Adipocytes; Aminoquinolines; Analysis; Animal tissues; Animals; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Antiviral drugs; Clinical medicine; Complications and side effects; Cytokines; Dendritic cells; Disease Models, Animal; DNA microarrays; Dosage and administration; Drug dosages; Drug therapy; Endocrinology; Enzymes; Feeds; Gene expression; Gene Expression Regulation - drug effects; Genes; Genetic aspects; Growth factors; Humans; Imiquimod; Inflammation; Interleukin 17; Interleukin 19; Interleukins - genetics; Internal medicine; Kinases; Male; Medicine; Metabolism; Mice; NF-κB protein; Pathways; Psoriasis; Psoriasis - chemically induced; Psoriasis - drug therapy; Psoriasis - genetics; Psoriasis - pathology; Quality; Resveratrol; Retinoic acid; Ribonucleic acid; RNA; Rodents; Signal transduction; Signal Transduction - drug effects; Signaling; Skin; Skin diseases; Slopes; Stilbenes - administration & dosage; Stilbenes - pharmacology; Thickness measurement
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0126599

The polyphenol resveratrol has anti-inflammatory effects in various cells, tissues, animals and human settings of low-grade inflammation. Psoriasis is a disease of both localized and systemic low-grade inflammation. The Sirtuin1 enzyme thought to mediate the effects of resveratrol is present in skin and resveratrol is known to down regulate NF-κB; an important contributor in the development of psoriasis. Consequently we investigated whether resveratrol has an effect on an Imiquimod induced psoriasis-like skin inflammation in mice and sought to identify candidate genes, pathways and interleukins mediating the effects. The study consisted of three treatment groups: A control group, an Imiquimod group and an Imiquimod+resveratrol group. Psoriasis severity was assessed using elements of the Psoriasis Area Severity Index, skin thickness measurements, and histological examination. We performed an RNA microarray from lesional skin and afterwards Ingenuity pathway analysis to identify affected signalling pathways. Our microarray was compared to a previously deposited microarray to determine if gene changes were psoriasis-like, and to a human microarray to determine if findings could be relevant in a human setting. Imiquimod treatment induced a psoriasis-like skin inflammation. Resveratrol significantly diminished the severity of the psoriasis-like skin inflammation. The RNA microarray revealed a psoriasis-like gene expression-profile in the Imiquimod treated group, and highlighted several resveratrol dependent changes in relevant genes, such as increased expression of genes associated with retinoic acid stimulation and reduced expression of genes involved in IL-17 dependent pathways. Quantitative PCR confirmed a resveratrol dependent decrease in mRNA levels of IL-17A and IL-19; both central in developing psoriasis. Resveratrol ameliorates psoriasis, and changes expression of retinoic acid stimulated genes, IL-17 signalling pathways, IL-17A and IL-19 mRNA levels in a beneficial manner, which suggests resveratrol, might have a role in the treatment of psoriasis and should be explored further in a human setting.